Table 1

Baseline characteristics of study participants

Characteristics per personBVB (n=28 eyes)TA (n=33 eyes)
Age* at the time of surgery, mean (95% CI), years70.2 (67.4–73.0)64.3 (61.1–67.5)†
Males‡, n (%)18 (64)24 (73)
Baseline HbA1c§, median (IQR),%7.5 (7–8.6)7.5 (6.3–8.4)
Diabetes‡, n (%)
 Type 101 (3)
 Type 2, requiring insulin17(61)21(64)
 Type 2, not requiring insulin11(39)11(33)
Characteristics per study eye
Left eyes, No. (%)10 (36)15 (46)
BCVA baseline, mean (95% CI), letters55.1 (48.7–61.4)50.5 (45.3–55.8)
CMT baseline, median (IQR), microns307.5 (277.5–391.5)316 (282–457)
DR severity, No. (%)
Mild1 (4)6 (19)
 Moderate13 (46)11 (33)
 Severe3 (11)5 (15)
 PRP only (inactive PDR)9 (32)11 (33)
 Treated PDR (active)2 (7)0
DMO at baseline, n (%)22 (79)26 (79)
Study eye was previously treated, prior¶ to study entry, n (%)
 Any treatment (TA, BVB or macular laser)¶14 (50)20 (61)
 Macular laser13 (46)18 (55)
 PRP Laser10 (36)9 (27)
 BVB3 (11)3 (9)
 TA1 (4)0
  • *The person’s age at the time of the eye’s surgery.

  • †Two-sample t-test, p value=0.007. All other comparisons were not significant (p>0.05).

  • ‡Count and percentage of eyes in the study that belong to a person with this characteristic.

  • §The person’s HbA1c levels at the time of the eye’s surgery.

  • ¶Previous treatments defined as BVB or TA received within 24 months prior to study entry and macular laser treatment at any time prior to study entry.

  • BCVA, best corrected visual acuity; BVB, bevacizumab; CMT, central macular thickness; DMO, diabetic macular oedema; DR, diabetic retinopathy; HbA1c, haemoglobin A1c; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation; TA, triamcinolone.